Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Sporn

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Antioxidants & Redox Signaling|September 8, 2007
Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophilsRajesh K Thimmulappa, Ralph J Fuchs, Deepti Malhotra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancerKaren Liby, Mara Rendi, Nanjoo Suh, et al.
Journal of Virology|March 16, 2005
Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulationNancy Vázquez, Teresa Greenwell-Wild, Nancy J Marinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapyKonstantin H Dragnev, Ian Pitha-Rowe, Yan Ma, et al.
Cancer Research|December 18, 2012
ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cellsAmanda L Balboni, Justine A Hutchinson, Andrew J DeCastro, et al.
Cancer Research|November 3, 2004
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemiaMarina Konopleva, Twee Tsao, Zeev Estrov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268Karen Liby, Renee Risingsong, Darlene B Royce, et al.
Cancer Research|May 20, 2004
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancerMara H Rendi, Nanjoo Suh, William W Lamph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivoAndrew E Place, Nanjoo Suh, Charlotte R Williams, et al.
Molecular Cancer Therapeutics|July 11, 2007
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activitiesKaren Liby, Tadashi Honda, Charlotte R Williams, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Antioxidants & Redox Signaling|September 8, 2007
Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophilsRajesh K Thimmulappa, Ralph J Fuchs, Deepti Malhotra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancerKaren Liby, Mara Rendi, Nanjoo Suh, et al.
Journal of Virology|March 16, 2005
Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulationNancy Vázquez, Teresa Greenwell-Wild, Nancy J Marinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapyKonstantin H Dragnev, Ian Pitha-Rowe, Yan Ma, et al.
Cancer Research|December 18, 2012
ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cellsAmanda L Balboni, Justine A Hutchinson, Andrew J DeCastro, et al.
Cancer Research|November 3, 2004
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemiaMarina Konopleva, Twee Tsao, Zeev Estrov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268Karen Liby, Renee Risingsong, Darlene B Royce, et al.
Cancer Research|May 20, 2004
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancerMara H Rendi, Nanjoo Suh, William W Lamph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivoAndrew E Place, Nanjoo Suh, Charlotte R Williams, et al.
Molecular Cancer Therapeutics|July 11, 2007
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activitiesKaren Liby, Tadashi Honda, Charlotte R Williams, et al.
Pageof 12